ArticleVirology journal2026
A receptor-Fc based SFV replicon Trim-Away platform for targeted viral protein degradation.
Article in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundDeveloping effective antiviral strategies is urgently needed during global viral pandemics. Traditional approaches, including small-molecule inhibitors, neutralizing antibodies, and RNA interference (RNAi), often face challenges such as drug resistance, limited specificity, and inefficient delivery. These limitations highlight the pressing need for innovative strategies focused on the targeted degradation of viral proteins.
methodsWe developed an optimized Trim-Away system employing a receptor-Fc fusion protein strategy. This system integrates the E3 ubiquitin ligase TRIM21 with engineered receptor-Fc proteins to ensure highly specific recognition and intracellular degradation. A key innovation is the use of the Semliki Forest virus (SFV) self-amplifying replicon (pSFV). This platform enables sustained and robust expression of the Trim-Away components. Furthermore, this plasmid-based delivery eliminates the need for protein purification, thereby streamlining the process and improving delivery efficiency.
resultsThe system effectively degrades diverse viral targets. Specifically, it successfully degraded the spike proteins of both wild-type SARS-CoV-2 and its Omicron variant. It also targeted adeno-associated virus (AAV) capsid proteins. In vivo assays further confirmed that the self-amplifying replicon markedly reduces AAV-encoded luciferase expression. These data demonstrate that the system maintains high potency even at low dosages.
conclusionsOur findings demonstrate that the pSFV-driven Trim-Away system is a powerful tool for viral protein degradation. The receptor-Fc strategy provides a significant advantage against rapidly mutating viruses. This study establishes a versatile and adaptable platform for future antiviral intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.